TCIM
ALDR

TIAA CREF Investment Management’s Alder Biopharmaceuticals ALDR Stock Holding History

TIAA CREF Investment Management’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$10.2M Sell
750,772
-644,837
-46% -$8.35M 0.01% 1029
2018
Q4 		$14.3M Buy
1,395,609
+346,476
+33% +$4.44M 0.01% 791
2018
Q3 		$17.5M Buy
1,049,133
+925,463
+748% +$16.7M 0.01% 795
2018
Q2 		$1.95M Sell
123,670
-51,620
-29% -$784K ﹤0.01% 2188
2018
Q1 		$2.23M Sell
175,290
-219,299
-56% -$3.17M ﹤0.01% 2045
2017
Q4 		$4.52M Buy
394,589
+229,010
+138% +$2.56M ﹤0.01% 1665
2017
Q3 		$2.03M Buy
165,579
+235
+0.1% +$2.45K ﹤0.01% 2158
2017
Q2 		$1.89M Buy
165,344
+22,277
+16% +$412K ﹤0.01% 2215
2017
Q1 		$2.98M Sell
143,067
-6,889
-5% -$153K ﹤0.01% 1905
2016
Q4 		$3.12M Buy
149,956
+8,744
+6% +$227K ﹤0.01% 1928
2016
Q3 		$4.63M Sell
141,212
-2,728
-2% -$83.1K ﹤0.01% 1660
2016
Q2 		$3.59M Buy
143,940
+74,036
+106% +$2M ﹤0.01% 1768
2016
Q1 		$1.71M Sell
69,904
-3,897
-5% -$90.2K ﹤0.01% 2169
2015
Q4 		$2.44M Hold
73,801
– – ﹤0.01% 2027
2015
Q3 		$2.42M Buy
73,801
+3,778
+5% +$161K ﹤0.01% 2032
2015
Q2 		$3.71M Buy
70,023
+36,450
+109% +$1.33M ﹤0.01% 1899
2015
Q1 		$969K Buy
33,573
+5,033
+18% +$138K ﹤0.01% 2637
2014
Q4 		$830K Sell
28,540
-5,044
-15% -$90.5K ﹤0.01% 2756
2014
Q3 		$426K Buy
33,584
+2,780
+9% +$42K ﹤0.01% 3010
2014
Q2 		$618K Buy
+30,804
New +$434K ﹤0.01% 2956

Other funds holding ALDR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

TIAA CREF Investment Management's ALDR Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Alder Biopharmaceuticals (ALDR) stake by 46% in Q1 2019, selling an estimated $8.35M and leaving 750,772 shares worth $10.2M. The position accounts for 0.01% of the portfolio, ranked #1029.

TIAA CREF Investment Management first reported a position in ALDR in Q2 2014 and has held it in 20 quarters since. The position peaked at $17.5M in Q3 2018. 123 funds tracked by Wall St. Rank hold ALDR as of Q1 2019.

  • TIAA CREF Investment Management held 750,772 shares of Alder Biopharmaceuticals worth $10.2M as of Q1 2019.
  • TIAA CREF Investment Management sold 644,837 Alder Biopharmaceuticals shares in Q1 2019, an estimated $8.35M.
  • Alder Biopharmaceuticals made up 0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1029 holding.
  • TIAA CREF Investment Management first reported a position in Alder Biopharmaceuticals in Q2 2014 and has held it in 20 quarters since.
  • TIAA CREF Investment Management's Alder Biopharmaceuticals position peaked at $17.5M in Q3 2018.
  • 123 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.